A pharma speakers bureau is only as strong as its speakers and the records behind them. That was true when we first wrote this guide in 2025. Going into 2027 it matters more. Enforcement keeps finding the same problems in speaker programs, and payment data is more public every year.
Below is what’s changed, then the three tips we’d focus on for the year ahead. If you’re new to how a bureau works, start with our explainer on the role of a pharmaceutical speakers bureau.
What’s changed for a pharma speakers bureau in 2027
The main reference is still the OIG Special Fraud Alert on speaker programs from November 2020. OIG said it was skeptical of the educational value of many speaker programs and listed warning signs. These include venues “not conducive to the exchange of educational information,” the same HCPs attending the same program more than once, and speakers picked because of what they prescribe. OIG did not ban speaker programs. It did make clear that the risk sits with the company running them. Our OIG compliance guide for speaker programs walks through each warning sign.
Recent settlements show those warning signs still drive cases:
- Takeda, May 2026. Takeda agreed to pay $13.67 million to resolve False Claims Act allegations about speaker programs for Trintellix. The government alleged high-end restaurant meals, duplicate programs on the same topic, and speakers selected to drive prescribing. Takeda did not admit liability. (DOJ announcement)
- Gilead, April 2025. Gilead agreed to pay $202 million to settle allegations that it used speaker programs, including programs at luxury restaurants, to pay kickbacks to doctors. (HHS-OIG summary)
Payment data is also easy to find. In July 2026, CMS published Program Year 2025 Open Payments data. It showed $14.67 billion in total payments, with $3.92 billion of that in general payments. (PALTmed summary) Speaker fees for events that aren’t continuing education fall under the CMS category for non-consulting services. Any HCP, reporter or competitor can look up what a speaker was paid.
The next deadline is close. Manufacturers must submit Program Year 2026 data by the 90th day of 2027, which is 31 March 2027 (42 CFR 403.908).
The PhRMA Code was revised in 2022 in response to the OIG alert. It’s voluntary, but many companies adopt it as policy. It bars alcohol at speaker programs, calls for modest venues, and says repeat attendance isn’t appropriate unless an attendee has a bona fide educational need. (Troutman summary) Our PhRMA Code guide for speaker programs covers the details.
What does this mean for your bureau?
Fewer speakers, chosen for clear reasons. Programs with a real educational purpose. And records that prove it.
Tip 1: Build your pharma speakers bureau around fit, not fame
The first instinct is often to sign the biggest names. National key opinion leaders do bring weight, especially at launch or when new data comes out. But community physicians often connect better with peers, because they see the same kinds of patients every week. Most bureaus need both. If you’re weighing the two, our guide on what a KOL is in pharma and our KOL engagement strategy for product launch can help.
Whoever you pick, judge every candidate on the same criteria:
- Clinical expertise. Real experience in the therapeutic area, and ideally current practice.
- Teaching skill. A strong researcher isn’t always a strong presenter. Watch a recording of them speaking if you can.
- Geography. Match speakers to where programs will actually run, so you aren’t paying for long-distance travel by default.
- Compliance history. Check exclusion lists such as the OIG LEIE, confirm licenses, and review how they handled past programs.
- Conflicts of interest. Ask about relationships with other companies and any roles that could raise questions.
Sales teams can help spot where education is needed. They shouldn’t pick the speakers. The 2020 alert lists sales influence over speaker selection, and selection tied to past or expected prescribing, among its warning signs. The Takeda allegations centered on the second.
So make selection a medical and compliance decision, with legal review where your policy calls for it. Write down why each speaker was chosen. That short note is often the first thing an auditor asks for.
Pay every speaker at fair market value, under a written agreement that spells out the services. Our guides on negotiating speaker agreements with HCPs and processing speaker honoraria cover contracts and payments step by step.
Tip 2: Keep your pharma speakers bureau lean and compliant
Bureaus tend to grow and rarely shrink. Speakers are added for a launch and stay on for years. Some give one program a year but still get paid for training. A large roster with low use is hard to justify, because it can look like payments without a real need.
These controls aren’t legal requirements on their own. They’re the good practice we see in well-run programs:
- Size the roster from the plan. Start with the number of programs you expect by region and topic. Work back to the speakers you need, plus a small bench for cancellations.
- Set an activity expectation. Review anyone who falls well below it at the annual check.
- Avoid repeat audiences. Don’t send the same HCPs to the same talk. Repeat attendance is one of the clearest red flags in both the OIG alert and the PhRMA Code.
- Review the roster every year. Look at exclusion checks, license status, FMV tier, utilization, attendee feedback and any compliance issues.
- Segment the bureau. Group speakers by therapy area, format and audience, so the right person gets the right program.
- Document the need for each program. Note the business reason, and set annual caps per speaker if your policy calls for them.
Venues and meals deserve their own check. Keep them modest, choose places suited to education, and follow your alcohol policy (PhRMA Code companies don’t serve it). Some states, including Vermont and Massachusetts, have their own gift, meal or disclosure rules. Our state-level compliance roadmap lists the main ones, and our speaker program budget benchmarks help you set realistic limits.
Virtual programs remove most venue risk. They still need a clear purpose, real attendance checks and the same content controls. See our virtual speaker program best practices.
Finally, track every payment as it happens. Applicable payments to covered recipients are reportable to Open Payments, subject to the rule’s definitions and exclusions. Covered recipients can review and dispute their data before CMS publishes it, so clean records save you time later. A lean bureau also makes the 31 March report far easier to get right.
Tip 3: Train pharma speakers bureau members in ways you can prove
Training is where speaker quality and compliance meet. A speaker who knows the data but drifts off-label is a risk. A speaker who knows the rules but can’t explain the data wastes the program.
Use the format that fits the moment:
- Live training meetings before a launch or a major data update.
- Virtual live sessions for spread-out rosters and quick updates.
- On-demand modules for new speakers and yearly refreshers.
Cover the same ground every time:
- The science and the approved deck. Speakers present approved, reviewed content and don’t edit the slides.
- Fair balance. Risk information is presented alongside benefits, consistent with the label.
- Q&A. Speakers answer within the approved content. Unsolicited off-label questions go to medical information, not to the speaker’s own view.
- Program rules. Meals, who can attend, sign-in, and what to do if something looks wrong.
Then make sure you can prove it. Keep completion records with dates and deck versions, signed attestations and short knowledge checks. Retrain when the label or the deck changes. Paid training time is a payment too, so it needs FMV and reporting. Our guide to the speaker briefing process for new clinical data shows how to run updates without slowing programs down.
Training only works if programs match it. Spot-audit live programs, compare sign-in sheets against your attendee rules, and flag repeat attendees before they become a pattern.
A 2027 readiness checklist for your pharma speakers bureau
- Every active speaker has a written selection rationale, signed off by medical and compliance.
- Exclusion and license checks are current for the whole roster.
- Contracts and FMV rates were reviewed in the last 12 months.
- Roster size matches the 2027 program plan.
- You can show who attended each program and spot repeat attendees.
- Venues and meal costs fit your policy and any state rules.
- Training records are tied to the current deck version.
- Program Year 2026 payments are reconciled well before 31 March 2027.
How ZHM helps you build a stronger speakers bureau
ZHM provides speaker bureau management for life sciences teams. That covers speaker contracting, logistics, payments and the records behind them. Our platform, Zvent.ai, is speaker management software that keeps speaker files, programs and spend in one place, so your reports and audits draw on the same data. It’s part of our wider HCP engagement platform.
See how one company ran its programs with us in the Verrica Pharmaceuticals case study, check pricing, or try Zvent.ai free.
This article is general information, not legal advice. Talk to your compliance and legal teams about how these rules apply to your programs.
Pharma speakers bureau FAQ
What is a pharma speakers bureau?
A pharma speakers bureau is a group of HCPs that a life sciences company contracts and trains to present approved content to other HCPs at speaker programs. Read more about speaker bureau programs.
Are speaker programs still allowed in 2027?
Yes. OIG did not ban them. It warned that programs with little educational value carry fraud and abuse risk, and recent settlements show it still acts on that.
How many speakers should a bureau have?
There’s no set number. Work back from your program plan by region and topic, then add a small bench.
Do speaker fees show up in Open Payments?
Yes, for covered recipients, subject to the rule’s exclusions. Speaker fees for non-CE events are reported as compensation for non-consulting services.
Should we run the bureau in-house or outsource it?
It depends on program volume and team size. Our outsourced vs in-house ROI analysis and our comparison of speaker bureau software vs full service can help you decide.
